LIPELLA PHARMACEUTICALS, INC.

Company Information

Company Name
LIPELLA PHARMACEUTICALS, INC.
Address
5414 GUARINO RD
PITTSBURGH, PA, 15217-1919
Phone
n/a
URL
n/a
DUNS
187190850
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$421,793.00
3
SBIR Phase II
$1,749,282.00
2
STTR Phase I
$740,688.00
1
STTR Phase II
$741,288.00
1
Chart code to be here

Award List

  1. Intravesical Liposome Treatment for Interstitial Cystitis

    Amount: $99,617.00

    DESCRIPTION (provided by applicant): Interstitial cystitis (IC) is a chronic, severely debilitating disease of the urinary bladder. It can be described as a chronic inflammatory condition of the bladd ...

    SBIR Phase I 2006 Department of Health and Human Services
  2. Intravesical Liposome Treatment for Interstitial Cystitis

    Amount: $750,000.00

    DESCRIPTION (provided by applicant): Interstitial cystitis (IC) is a chronic, severely debilitating disease of the urinary bladder. It can be described as a chronic inflammatory condition of the bladd ...

    SBIR Phase II 2008 Department of Health and Human Services
  3. Bladder drug delivery using intravesical liposomes to treat overactive bladder

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Lipella Pharmaceutical Inc has been successful with development of intravesical liposome for painful bladder syndrome/Interstitial cystitis (PBS/IC). Through SB ...

    SBIR Phase I 2009 Department of Health and Human Services
  4. Developing Intravesical Liposomes for Interstitial Cystitis

    Amount: $740,688.00

    DESCRIPTION (provided by applicant): LP08 is a novel intravesical treatment for interstitial cystitis (IC), a poorly understood chronic disorder of unknown etiology consisting of irritative bladder sy ...

    STTR Phase I 2009 Department of Health and Human Services
  5. Bladder drug delivery using intravesical liposomes to treat overactive bladder

    Amount: $999,282.00

    DESCRIPTION (provided by applicant): Lipella Pharmaceuticals Inc. has been funded by National Institutes of Health Small Business Innovation and Research (SBIR) grants to develop intravesical liposom ...

    SBIR Phase II 2011 Department of Health and Human Services
  6. Preclinical Development of Tacrolimus for Radiation Cystitis

    Amount: $222,176.00

    DESCRIPTION (provided by applicant): This project, entitied Preclinical Development of Tracrolimus for Radiation Cystitis will fund key experiments to advance the commercial development of LP-10. LP ...

    SBIR Phase I 2014 Department of Health and Human Services
  7. Developing Intravesical Liposomes for Interstitial Cystitis

    Amount: $741,288.00

    DESCRIPTION (provided by applicant): Lipella Pharmaceuticals Inc. (Pittsburgh, PA) is a clinical-stage pharmaceutical company specializing in intravesical therapies for urinary bladder dysfunctions. L ...

    STTR Phase II 2014 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government